As part of this ongoing commitment to our audience, we are pleased to announce an exclusive interview with Dr. Martin Lechmann, Associate Director for Bioanalytics, Immunogenicity, and DMPK, Non-Clinical Development, at Merck Serono.
Dr. Lechmann’s interview addresses potential pharmacokinetic and pharmacodynamic biomarkers for immunogenicity, mechanisms for improving drug tolerability, immunoassay reliability, and other major concerns now facing the industry. Please click here to download the interview.
Download Dr. Lechmann’s podcast here.
Here's an excerpt from the article:
Now, can we delve into that a little bit? What are some of the challenges that are involved in using PD activity as a biomarker for immunogenicity? If they can be overcome, what are the specific benefits?Dr. Lechmann's response: Yes, of course. First of all, you have to have an appropriate biomarker in your hands. In many cases, it is very difficult to achieve this. Of course, then if you have the biomarker, you have to have a very good understanding of the biology of the biomarker and to see if it is an early biomarker or late biomarker. And furthermore, it’s very crucial, also, to see how you determine what the kind of assay is to determine the concentration of the biomarkers. So, the capability of the biomarker. I think these are the challenges that you face with PD markers.
Immunogenicity for Biotherapeutics can help you find more answers about designing worthwhile assays and safer molecular configurations. To find out more about the event, download the brochure.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment